Related references
Note: Only part of the references are listed.Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy
Lorenzo Fornaro et al.
FUTURE ONCOLOGY (2014)
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
Yoon-Koo Kang et al.
INVESTIGATIONAL NEW DRUGS (2014)
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors
N. Yamamoto et al.
ANNALS OF ONCOLOGY (2013)
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer
N. Yamamoto et al.
BRITISH JOURNAL OF CANCER (2013)
Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
Shunsuke Kondo et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro et al.
LANCET ONCOLOGY (2013)
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2012)
Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
Roger B. Cohen et al.
INVESTIGATIONAL NEW DRUGS (2012)
Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
Alex A. Adjei et al.
ONCOLOGIST (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Liver disease selectively modulates cytochrome P450-mediated metabolism
Reginald F. Frye et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort
JA Marrero et al.
HEPATOLOGY (2005)
Share Paper
